Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $13.00.

STTK has been the topic of several research reports. Wall Street Zen downgraded Shattuck Labs from a “buy” rating to a “hold” rating in a report on Saturday. TD Cowen reaffirmed a “buy” rating on shares of Shattuck Labs in a report on Friday, March 6th. Piper Sandler assumed coverage on Shattuck Labs in a report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price objective on the stock. Needham & Company LLC assumed coverage on shares of Shattuck Labs in a research report on Friday, March 6th. They set a “buy” rating and a $25.00 target price for the company. Finally, Weiss Ratings upgraded shares of Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday.

Insider Activity at Shattuck Labs

In other Shattuck Labs news, insider Arundathy N. Pandite sold 30,000 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $6.61, for a total transaction of $198,300.00. Following the completion of the sale, the insider owned 166,219 shares in the company, valued at approximately $1,098,707.59. The trade was a 15.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 8.79% of the company’s stock.

Institutional Trading of Shattuck Labs

Several institutional investors and hedge funds have recently made changes to their positions in the business. Orbimed Advisors LLC bought a new stake in shares of Shattuck Labs during the 3rd quarter valued at $15,072,000. NEXTBio Capital Management LP bought a new stake in shares of Shattuck Labs during the 4th quarter valued at $11,497,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Shattuck Labs during the 4th quarter valued at $7,031,000. Pinnacle Associates Ltd. raised its position in shares of Shattuck Labs by 1.8% during the 3rd quarter. Pinnacle Associates Ltd. now owns 1,388,723 shares of the company’s stock valued at $3,319,000 after acquiring an additional 25,000 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in shares of Shattuck Labs during the 4th quarter valued at $4,945,000. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Stock Performance

NASDAQ:STTK opened at $6.10 on Friday. The stock’s fifty day moving average price is $6.67 and its two-hundred day moving average price is $4.62. Shattuck Labs has a 52-week low of $0.71 and a 52-week high of $8.33. The company has a market cap of $467.75 million, a price-to-earnings ratio of -9.68 and a beta of 1.18.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.01. During the same period last year, the company posted ($0.27) EPS. On average, equities analysts predict that Shattuck Labs will post -0.51 EPS for the current fiscal year.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical?stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten?carrier conjugate technology designed to generate high?affinity drug?specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood?brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.